United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP
Friday, 15 March 2024
On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's proposed biosimilar to EYLEA.
On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's proposed biosimilar to EYLEA.
|
||||
You Might LikeRelated news from verified sources
|